Anna Linda Zignego

About Anna Linda Zignego

Anna Linda Zignego, With an exceptional h-index of 70 and a recent h-index of 33 (since 2020), a distinguished researcher at Università degli Studi di Firenze, specializes in the field of Primo interesse, secondo interesse.

His recent articles reflect a diverse array of research interests and contributions to the field:

Predicting de‐novo portal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort

Prevalence and Characterization of Resistance Profiles of “Unusual” HCV Subtypes in Italy within the Italian Resistance Network Vironet C

Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)

Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

Correction to: Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis

Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired …

Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative …

Anna Linda Zignego Information

University

Position

Centro Interdipartimentale MASVE DMCS

Citations(all)

24079

Citations(since 2020)

4391

Cited By

21803

hIndex(all)

70

hIndex(since 2020)

33

i10Index(all)

213

i10Index(since 2020)

114

Email

University Profile Page

Google Scholar

Anna Linda Zignego Skills & Research Interests

Primo interesse

secondo interesse

Top articles of Anna Linda Zignego

Predicting de‐novo portal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort

United European Gastroenterology Journal

2023/11/30

Prevalence and Characterization of Resistance Profiles of “Unusual” HCV Subtypes in Italy within the Italian Resistance Network Vironet C

Digestive and Liver Disease

2024/2/1

Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)

Viruses

2024/4/26

Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

2023/2

Correction to: Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

Clinical Rheumatology

2023

COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis

Clinical and Experimental Rheumatology

2023

Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired …

Journal of Translational Autoimmunity

2023/12/1

Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative …

British Journal of Haematology

2023/10

Laura Gragnani
Laura Gragnani

H-Index: 18

Anna Linda Zignego
Anna Linda Zignego

H-Index: 39

Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals

Journal of Personalized Medicine

2023/7/26

Serological and molecular characterization of hepatitis C virus-related cryoglobulinemic vasculitis in patients without cryoprecipitate

International Journal of Molecular Sciences

2023/7/18

AB1291 COVID-19 AND CRYOGLOBULINEMIC VASCULITIS. LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT’S POPULATION

2023/6/1

COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity

2023/5

Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

International Journal of Infectious Diseases

2023/4/1

POS1267 LONG-TERM SURVEY STUDY OF THE IMPACT OF COVID-19 ON SYSTEMIC AUTOIMMUNE DISEASES. LOW DEATH RATE DESPITE THE INCREASED PREVALENCE OF SYMPTOMATIC INFECTION. ROLE OF PRE …

2022/6/1

POS1214 COVID-19 VACCINATION RATE AND SAFETY PROFILE IN PATIENTS AFFECTED BY MIXED CRYOGLOBULINEMIC VASCULITIS.

2022/6/1

Epidemiological, virological and clinical profile of HBsAg positive individuals in Italian hospital settings: interim results of the HBV/HDV PITER cohort

Digestive and Liver Disease

2022/3/1

Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2

Annals of the rheumatic diseases

2022/3/1

COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies

Journal of Translational Autoimmunity

2022/1/1

Laura Gragnani
Laura Gragnani

H-Index: 18

Anna Linda Zignego
Anna Linda Zignego

H-Index: 39

Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis

Clinical Rheumatology

2022/1

See List of Professors in Anna Linda Zignego University(Università degli Studi di Firenze)